Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients
Recruiting
- Conditions
- Acute Coronary Syndrome
- Registration Number
- NCT06567418
- Lead Sponsor
- Yun Dai Chen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10000
Inclusion Criteria
Inclusion Criteria:<br><br> - Patients diagnosed with Acute Coronary Syndrome (ACS) upon hospital admission.<br><br> - Patients aged 18 years or older.<br><br> - Patients who received Alirocumab 75 mg in combination with statin therapy ±<br> Ezetimibe as the intervention group, and those treated exclusively with statin<br> therapy ± Ezetimibe as the control group, either during hospitalization or at<br> discharge.<br><br> - Patients with at least one follow-up record.<br><br>Exclusion Criteria:<br><br> - Patients who received Evolocumab treatment at any time.<br><br> - Patients who received Inclisiran treatment at any time.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint is the risk of MACE within 1 year of follow-up
- Secondary Outcome Measures
Name Time Method Percentage reduction of LDL-C levels at 1-month follow-up from baseline;Proportion of patient who achieved LDL-C goal (<1.4mmol/L) at 1-month follow-up